This case involves several autistic male children who developed gynecomastia after taking the drug risperidone. It was alleged that the pharmaceutical company that marketed this drug hid evidence that would have alerted clinicians and regulatory authorities to the connection between risperidone, increased prolactin, and gynecomastia. An early study on the drug’s side effects allegedly included multiple data sets that reported a direct link between increased prolactin levels and side effects like gynecomastia. These findings were allegedly redacted from the published manuscript and the published version concluded that the drug produced no prolactin-associated side effects. An expert in statistics was sought to review the original drug report and determine whether this paper should be retracted and what data any retraction would cover.